Literature DB >> 12781078

Treatment options for brain metastases in patients with non-small-cell lung cancer.

Sadaf Taimur1, Martin J Edelman.   

Abstract

Brain metastases are a common complication for patients with non-small-cell lung cancer and a significant cause of morbidity and mortality. In the past, treatment of brain metastases and lung cancer focused on symptom palliation with whole-brain radiotherapy (WBRT) and steroids because of the grim outlook for patients. However, recent advances in technology and surgical techniques have created more options for the management of brain metastases, which include surgery, irradiation, stereotactic radiosurgery, and chemotherapy. These aggressive approaches have resulted in an improvement of neurologic outcomes and survival rates of patients with non-small-cell lung cancer. Central nervous system (CNS) metastases can be divided into three groups: solitary CNS metastases with controlled or controllable primary disease, oligometastatic disease (fewer than 3 metastases), and multiple metastases. For patients with solitary CNS metastases, long-term survival is possible. A radical treatment approach involving surgical resection or radiosurgery, followed by WBRT, is recommended. For patients with oligometastatic disease, surgical resection or radiosurgery is considered in selected cases and WBRT is indicated. For patients with multiple metastases, WBRT is recommended. For patients with oligometastatic disease and those with multiple metastases, recent evidence indicates that systemically effective chemotherapy may produce responses and can be instituted safely before radiotherapy. The treatment timing of chemotherapy and radiotherapy should be individualized.

Entities:  

Mesh:

Year:  2003        PMID: 12781078     DOI: 10.1007/s11912-003-0077-8

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  33 in total

1.  Comparison of three treatment options for single brain metastasis from lung cancer.

Authors:  B Li; J Yu; M Suntharalingam; A S Kennedy; P P Amin; Z Chen; R Yin; S Guo; T Han; Y Wang; N Yu; G Song; L Wang
Journal:  Int J Cancer       Date:  2000-02-20       Impact factor: 7.396

2.  Radiosurgery for brain metastases from primary lung carcinoma.

Authors:  R Hoffman; P K Sneed; M W McDermott; S Chang; K R Lamborn; E Park; W M Wara; D A Larson
Journal:  Cancer J       Date:  2001 Mar-Apr       Impact factor: 3.360

3.  Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160).

Authors:  V W Rusch; D J Giroux; M J Kraut; J Crowley; M Hazuka; D Johnson; M Goldberg; F Detterbeck; F Shepherd; R Burkes; T Winton; C Deschamps; R Livingston; D Gandara
Journal:  J Thorac Cardiovasc Surg       Date:  2001-03       Impact factor: 5.209

4.  Interference in the effect of dexamethasone by diphenylhydantoin.

Authors:  E E Werk; Y Choi; L Sholiton; C Olinger; N Haque
Journal:  N Engl J Med       Date:  1969-07-03       Impact factor: 91.245

5.  Factors influencing survival after gamma knife radiosurgery for patients with single and multiple brain metastases.

Authors:  H K Shu; P K Sneed; C Y Shiau; M W McDermott; K R Lamborn; E Park; M Ho; P L Petti; V Smith; L J Verhey; W M Wara; P H Gutin; D A Larson
Journal:  Cancer J Sci Am       Date:  1996 Nov-Dec

6.  Radiosurgery for brain metastases: is whole brain radiotherapy necessary?

Authors:  P K Sneed; K R Lamborn; J M Forstner; M W McDermott; S Chang; E Park; P H Gutin; T L Phillips; W M Wara; D A Larson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-02-01       Impact factor: 7.038

7.  Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group.

Authors:  R Komaki; C B Scott; W T Sause; D H Johnson; S G Taylor; J S Lee; B Emami; R W Byhardt; W J Curran; A R Dar; J D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-10-01       Impact factor: 7.038

8.  Phenytoin-dexamethasone interaction: a previously unreported observation.

Authors:  L A Lawson; R A Blouin; R B Smith; R P Rapp; A B Young
Journal:  Surg Neurol       Date:  1981-07

Review 9.  Advanced non-small cell lung cancer.

Authors:  M J Edelman; S L Khanwani
Journal:  Curr Treat Options Oncol       Date:  2001-02

10.  Defining the role of radiosurgery in the management of brain metastases.

Authors:  M P Mehta; J M Rozental; A B Levin; T R Mackie; S S Kubsad; M A Gehring; T J Kinsella
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

View more
  5 in total

Review 1.  RNA interference and nonviral targeted gene therapy of experimental brain cancer.

Authors:  Ruben J Boado
Journal:  NeuroRx       Date:  2005-01

2.  Examination of blood-brain barrier (BBB) integrity in a mouse brain tumor model.

Authors:  Ngoc H On; Ryan Mitchell; Sanjot D Savant; Corbin J Bachmeier; Grant M Hatch; Donald W Miller
Journal:  J Neurooncol       Date:  2012-11-27       Impact factor: 4.130

3.  Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study.

Authors:  Zhi-Yong He; Mei-Fang Li; Jing-Hui Lin; Dong Lin; Ren-Jang Lin
Journal:  Cancer Manag Res       Date:  2019-03-14       Impact factor: 3.989

4.  Computer Tomography Radiomics-Based Nomogram in the Survival Prediction for Brain Metastases From Non-Small Cell Lung Cancer Underwent Whole Brain Radiotherapy.

Authors:  Ji Zhang; Juebin Jin; Yao Ai; Kecheng Zhu; Chengjian Xiao; Congying Xie; Xiance Jin
Journal:  Front Oncol       Date:  2021-02-11       Impact factor: 6.244

5.  Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer.

Authors:  Qing Chen; Adrienne Boire; Xin Jin; Manuel Valiente; Ekrem Emrah Er; Alejandro Lopez-Soto; Leni Jacob; Ruzeen Patwa; Hardik Shah; Ke Xu; Justin R Cross; Joan Massagué
Journal:  Nature       Date:  2016-05-18       Impact factor: 49.962

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.